The present disclosure provides systems and methods relating to neuromodulation. In particular, the present disclosure provides systems and methods for eliminating the onset response when blocking neural conduction. The various embodiments disclosed herein include methods and systems for delivering treatment based on blocking waveforms to subjects with pathological neural activity.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
A61N 1/06 - Electrodes pour traitement à haute fréquence
2.
SPLICE SWITCHING OLIGONUCLEOTIDES TO RESTORE PHKG2 EXPRESSION IN GLYCOGEN STORAGE DISEASE IX
The present disclosure provides methods and compositions for the treatment of glycogen storage diseases (e.g., GSD IX). In some aspects, the present disclosure provides splice-switching oligonucleotides that correct splicing defects and methods of using these splice-switching oligonucleotides to treat glycogen storage diseases (e.g., GSD IX). In a further aspect, the disclosure provides a method for creating cell models for the identification and characterization of pathogenic RNA splicing defects.
A61K 31/712 - Acides nucléiques ou oligonucléotides ayant des sucres modifiés, c. à d. autres que le ribose ou le 2'-désoxyribose
A61K 31/7125 - Acides nucléiques ou oligonucléotides ayant des liaisons internucléosides modifiées, c. à d. autres que des liaisons 3'-5' phosphodiester
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Disclosed herein are Cas12a fusion proteins. The Cas12a fusion proteins may comprise, for example p300 or SID. Further provided are DNA constructs encoding at least one gRNA, such as an array of multiple gRNAs. The Cas12a fusion proteins and gRNAs may be used to modulate expression of a gene.
A brain computer interface for interfacing with a brain of a subject is provided. The brain computer interface includes one or more shanks. Each shank includes an array of pixels and output traces. Each pixel includes an electrode and a front-end circuit positioned at a site of the electrode. The front-end circuit is configured to reduce noise in signals recorded by the electrode, and further configured to multiplex the signals. A density of power consumption of the each pixel is equal to or less than 1 µW per area of 50 µm by 50 µm. The output traces are electrically coupled with the array of pixels. A number of output traces is less than a number of pixels in the array due to multiplexing. The one or more shanks are configured to be inserted on and/or into a brain of a subject.
The present disclosure describes, in part, compositions comprising prodrugs of hydroxamate-based compounds, such as LpxC inhibitors, and methods of making and using same.
The present disclosure provides, in part, methods of eliciting immuno-tolerance using truncated membrane-bound and soluble immune checkpoints. Constructs comprising the immune checkpoint protein or portions thereof capable of binding to and activating the immune checkpoint proteins receptor are provided. The nucleic acid encoding the immune checkpoint protein or portion thereof is operably connected to a promoter and optionally also a secretory signal to allow for secretion of the immune checkpoint protein or portion thereof. The constructs may include a viral vector which can be used to deliver or introduce the construct into a transplantable article or organ.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
7.
COMPOSITIONS AND METHODS FOR THE ENHANCEMENT OF IMMUNE CELL ACTIVITIES AGAINST CANCER
Disclosed herein are compositions comprising a recombinant polypeptide targeting phosphatidylserine on the surface of cancer cells and methods of using the compositions to treat a cancer in a subject.
Aspects of the present disclosure relate generally to systems and methods for use in the implementation and/or operation of quantum information processing (QIP) systems, and more particularly, to methods and systems for improving vacuum in compact room temperature packages. An exemplary' method for preparing a vacuum chamber for a QIP system includes inserting, into a processing vacuum chamber, a lid having a shadow mask on an optical window, coating the inside of the lid with a getter material; removing the shadow mask from the optical window; and providing an ion trap package in the processing vacuum chamber and welding the lid on a top of the ion trap package to prepare the vacuum chamber.
A thermoacoustic measurement probe may include an open-ended hollow radio-frequency (RF) waveguide; and a thermoacoustic transducer, wherein the open-ended hollow RF waveguide, in the form of a sleeve, surrounds and is mechanically joined to the thermoacoustic transducer.
H01P 11/00 - Appareils ou procédés spécialement adaptés à la fabrication de guides d'ondes, résonateurs, lignes ou autres dispositifs du type guide d'ondes
10.
HIV VACCINE IMMUNOGENS FOR THE INDUCTION OF V3-GLYCAN TARGETING ANTIBODIES
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
Provided herein are methods for determining whether a drug impacts ubiquitination of G-coupled protein receptors (GPCRs) and the downstream transducer-mediated signaling of the GPCRs. Also provided are proteins, nucleic acids, vectors, constructs, host cells, and kits for performing these methods.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p.ex. basé sur des systèmes experts médicaux
12.
EPIGENETIC MODULATION OF GENOMIC TARGETS TO CONTROL EXPRESSION OF PWS-ASSOCIATED GENES
Disclosed herein are DNA targeting systems that target a regulatory element of a gene within the 15q11-13 locus. Further provided are DNA targeting systems including at least one gRNA and a Cas9 protein, as well as compositions comprising the same. The compositions may be used in methods for treating Prader-Willi Syndrome (PWS) in a subject. The method may include administering to a subject the DNA targeting system.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
The present disclosure provides methods for classifying and treating gastrointestinal tumors in a patient based on tumor-associated mycobiota. Also disclosed herein are methods for determining the prognosis of patients suffering from GI cancers comprising detecting the presence of tumor associated Candida nucleic acids in a biological sample obtained from the GI cancer patients.
C12Q 1/6895 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les plantes, les champignons ou les algues
14.
TECHNOLOGIES FOR SCAFFOLD AND VOID SPACE ANALYSIS OF GRANULAR PARTICLE SCAFFOLDS
Technologies for particle scaffold analysis include a computing device that obtains labeled input data indicative of particles positioned in a scaffold domain. The input data may be generated by an imaging system coupled to the computing device or may be generated by simulating a physical system. The computing device determines a cumulative Euclidean distance transform (EDT) for each voxel of void space of the scaffold domain, and determines multiple medial axis landmarks based on the EDT and on a particle configuration. The particle configuration is indicative of a neighboring particle graph. The computing device segments the void space into multiple subunits based on the medial axis landmarks. The computing device may determine multiple scaffold descriptors based on the subunits. Other embodiments are described and claimed.
A61L 27/40 - Matériaux composites, c. à d. en couches ou contenant un matériau dispersé dans une matrice constituée d'un matériau analogue ou différent
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
DUKE UNIVERSITY (USA)
Inventeur(s)
Zenhausern, Frederic
Vo-Dinh, Tuan
Atta, Supriya
Abrégé
A method for storage of digital information via a biopolymer includes: receiving digital information; designing a target biopolymer sequence; encoding the digital information; synthesizing the target biopolymer sequence via a layered microfluidic device, the microfluidic device including: a pneumatic control layer configured to supply a control gas to a plurality of pneumatically operated valves; a fluidic layer comprising an interconnected matrix of microfluidic channels; and a biopolymer analysis layer comprising solid-state nanopores disposed in a semiconductor support. The method may also include: analyzing the target biopolymer sequence via the solid-state nanopores; transferring the target biopolymer sequence to a biopolymer preservation system; storing the target biopolymer sequence in the biopolymer preservation system; retrieving the target biopolymer sequence from the biopolymer preservation system; and decoding the target biopolymer sequence into the digital information.
G06N 3/00 - Agencements informatiques fondés sur des modèles biologiques
G06N 3/12 - Agencements informatiques fondés sur des modèles biologiques utilisant des modèles génétiques
G11C 13/02 - Mémoires numériques caractérisées par l'utilisation d'éléments d'emmagasinage non couverts par les groupes , ou utilisant des éléments dont le fonctionnement dépend d'un changement chimique
G16B 30/00 - TIC spécialement adaptées à l’analyse de séquences impliquant des nucléotides ou des aminoacides
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
16.
SUBLINGUAL NANOFIBER VACCINES AND METHODS OF MAKING AND USING SAME
Embodiments are directed to a UPEC conjugate peptide including a self- assembling peptide and at least one UPEC epitope. The UPEC conjugate peptide may self- assemble into a nanofiber or fibril. Compositions including the UPEC conjugate peptide may be used to treat a bacterial infection such as a urinary tract infection (UTI). The compositions and methods may be specific for pathogenic bacteria. The compositions and methods may treat the infection without altering the gut microbiome.
A method of selectively heating a lesion or tumor using laser therapy treatment includes administering plasmonic metal nanoplatforms to a subject having the lesion or tumor and administering laser therapy treatment to the lesion or tumor. The plasmonic metal nanoplatforms selectively accumulate in the lesion or tumor and the laser therapy is strongly absorbed by the plasmonic metal nanoplatforms that are accumulated in the lesion or tumor. The plasmonic metal nanoplatforms fill the contours of the lesion or tumor thereby enabling laser treatment in a conformal way. The plasmonic metal nanoplatforms selectively accumulate in the lesion or tumor produce efficient photon-to-heat conversion, thus transforming them into heat sources, leading to efficient heat transport, thereby inducing a larger treatment area.
A23L 3/26 - Conservation des aliments ou produits alimentaires, en général, p.ex. pasteurisation ou stérilisation, spécialement adaptée aux aliments ou produits alimentaires par irradiation sans chauffage
A61L 2/02 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des phénomènes physiques
A61L 2/08 - Procédés ou appareils de désinfection ou de stérilisation de matériaux ou d'objets autres que les denrées alimentaires ou les lentilles de contact; Accessoires à cet effet utilisant des phénomènes physiques des radiations
18.
PROTEIN LIBRARY DISPLAY SYSTEMS AND METHODS THEREOF
Disclosed herein are protein-RNA display constructs that couple a protein of interest to its encoding mRNA. An example protein-RNA display construct includes a first nucleotide portion including an RNA that forms hairpin structures; a second nucleotide portion including an mRNA encoding a protein of interest; a first protein portion including a protein having RNA hairpin binding peptides that can specifically bind to the RNA hairpin structures; and a second protein portion including the protein of interest. The protein-RNA display constructs take advantage of binding interactions between RNA hairpin structures and RNA hairpin binding peptides to stably couple the protein of interest to its encoding mRNA. Also disclosed are nucleic acids encoding the protein-RNA display constructs, libraries and kits including the protein-RNA display constructs, and methods of using the protein-RNA display constructs in high-throughput display applications.
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
C07K 14/195 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
C40B 40/10 - Bibliothèques comprenant des peptides ou des polypeptides ou leurs dérivés
C40B 70/00 - CHIMIE COMBINATOIRE; BIBLIOTHÈQUES, p.ex. CHIMIOTHÈQUES Étiquettes ["tags"] ou marqueurs ["labels"] spécialement adaptés à la chimie combinatoire ou aux chimiothèques, p.ex. "tags" fluorescents ou codes-barres
19.
NOVEL EQUILIBRATIVE NUCLEOSIDE TRANSPORTER INHIBITORS AND METHODS OF MAKING AND USING SAME
Described herein are equilibrative nucleoside transporter inhibitors and methods of making and using same. In some embodiments, the inhibitors are used for the prevention and/or treatment of pain.
The present disclosure describes, in part, a method for achieving depiction of mixtures of chemically shifted and on-resonance moieties using magnetic resonance imaging (MRI) technology. The method can use a steady-state free precession sequence that can be optimized so that the chemically shifted moiety is in an out-of-phase passband in relation to the on-resonance moiety. This feature can enable detection of tissues with a small amount of the chemically shifted moiety with high sensitivity, including but not limited to detecting fat and water when imaging an organ.
G01R 33/485 - Systèmes d'imagerie RMN avec sélection de signaux ou de spectres de régions particulières du volume, p.ex. spectroscopie in vivo basés sur l'information de déplacement chimique
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
G01R 33/50 - Systèmes d'imagerie RMN basés sur la détermination des temps de relaxation
G01R 33/56 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne
21.
CH505 ENVELOPES TO ENGAGE AND MATURE CD4 BINDING SITE NEUTRALIZING ANTIBODIES
In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelopes with optimized sequences for antibody induction. In some embodiments, the invention provides mRNA sequences of said HIV-1 immunogens.
An excretion collection and evaluation system including at least one waste receptacle including a waste collection area, and a sensor configured to be coupled to a toilet, selectively coupled to the at least one waste receptable, and configured to generate a signal indicative of a quantity of waste deposited in the waste collection area.
A61B 10/00 - Autres méthodes ou instruments pour le diagnostic, p.ex. pour le diagnostic de vaccination; Détermination du sexe; Détermination de la période d'ovulation; Instruments pour gratter la gorge
G01F 19/00 - Récipients de mesure calibrés pour des fluides ou des matériaux solides fluents, p.ex. bechers gradués
G01N 1/00 - Echantillonnage; Préparation des éprouvettes pour la recherche
G01N 33/483 - Analyse physique de matériau biologique
G01F 23/00 - Indication ou mesure du niveau des liquides ou des matériaux solides fluents, p.ex. indication en fonction du volume ou indication au moyen d'un signal d'alarme
The present invention provides a tri-arm star bottlebrush polymer or copolymer that can be photocrosslinked to form a solvent free soft and optically clear elastomeric gel with a specific refractive index and Young's Modulus, making it suitable for implantation and for use as an accommodating intraocular lens (IOL), a pseudoaccomodating, presbyopia correcting IOL, or a custom-molded IOL. In various embodiments, the tri-arm star bottlebrush polymer is formed using a trifunctional reversible addition fragmentation chain-transfer (RAFT) agent and will have three methacrylate and/or acrylate polymer chains extending therefrom. These methacrylate polymer chains comprising the polymerized residues of a methacrylate macromonomer and one or more hydroxy-functionalized methacrylate chain extenders with alkene functional groups covalently bonded thereto. In some of these embodiments, the thiol containing end groups of the trifunctional RAFT agent, if any, are removed using a thermally or chemically activated radical generating compound to produce an optically clear polymer.
C08F 293/00 - Composés macromoléculaires obtenus par polymérisation sur une macromolécule contenant des groupes capables d'amorcer la formation de nouvelles chaînes polymères rattachées exclusivement à une ou aux deux extrémités de la macromolécule de départ
G02B 1/04 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques faits de substances organiques, p.ex. plastiques
B29D 11/00 - Fabrication d'éléments optiques, p.ex. lentilles ou prismes
25.
COMPOUNDS, COMPOSITIONS, AND METHODS FOR CELL-SPECIFIC PHARMACOLOGY
Disclosed herein are compounds that have improved cellular specificity. The compounds have linkers and other moieties that can both aid in cellular specificity and that can attach functional groups to a target cell. The compounds can be used, e.g., in methods of modulating, detecting, and labeling of proteins and cells. An example method includes the compound forming a covalent bond with a dehalogenase variant.
C12Q 1/34 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir une hydrolase
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
G01N 33/543 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
Methods and materials for generating and using patient-derived MicroOrganoSpheres (e.g., MicroOrganoSpheres derived from tumor tissue) are provided herein.
Cellulose-reinforced hydrogels may include a cellulose nanofiber network and an interstitial hydrogel portion within interstitial regions of the cellulose nanofiber network, the interstitial hydrogel portion comprising polyvinyl alcohol (PVA), wherein the hydrogel component has a crystallinity of 20% or greater.
Embodiments are directed to a phosphorylcholine (PC)-conjugate peptide including a self-assembling peptide and at least one PC molecule. The PC-conjugate peptide may self-assemble into a nanofiber or fibril. Compositions including the PC-conjugate peptide may be used to elicit an immune response, such as stimulating B1a cells to produce antibodies. The compositions may be used to treat an inflammatory disease such as inflammatory bowel disease (IBD) or ulcerative colitis. The compositions may also be used to alter the gut microbiome.
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 39/385 - Haptènes ou antigènes, liés à des supports
A61K 47/42 - Protéines; Polypeptides; Leurs produits de dégradation; Leurs dérivés p.ex. albumine, gélatine ou zéine
A61K 38/08 - Peptides ayant de 5 à 11 amino-acides
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C07K 1/10 - Procédés généraux de préparation de peptides utilisant des agents de couplage
29.
BIOMATERIALS FOR IMPROVING BRAIN HEALING AFTER STROKE AND METHODS OF USING SAME
Astrocytes are known to regulate the body responses to diseases and injuries in central nervous system (CNS). Embodiments of the instant disclosure relate to biomaterial for delivering extracellular vesicles derived from reactive cell populations for improving brain healing after injury. Also provided are methods of improving angiogenesis, axonogenesis, or inducing tissue repair using the disclosed biomaterials. Also provided are methods of making the biomaterials.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 47/06 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite
A61K 47/54 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique
The present disclosure describes, in part, compositions and methods for preventing and treating cardiovascular disease, atherosclerosis and inflammation by inhibiting or decreasing production, expression or activity of Rpl13 snoRNA.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
C12N 15/00 - Techniques de mutation ou génie génétique; ADN ou ARN concernant le génie génétique, vecteurs, p.ex. plasmides, ou leur isolement, leur préparation ou leur purification; Utilisation d'hôtes pour ceux-ci
The present disclosure provides compositions and methods for treating and preventing pancreatitis. Particularly, the disclosure provides methods for treating and preventing pancreatitis using a nicotinic acetylcholine receptor agonist.
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p.ex. enzymes pancréatiques
A61K 31/09 - Ethers ou acétals ayant une liaison éther à un carbone cyclique d'un noyau aromatique ayant plusieurs liaisons éther
A61K 31/435 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
32.
RECOMBINANT TIM-4 PROTEIN, CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL DELIVERY SYSTEM AND METHODS OF MAKING AND USING SAME
The present invention provides recombinant TIM-4 fusion proteins comprising a domain of TIM-4 and a scFv specific for CD3 and methods of making and using the same. The fusion proteins provided herein may be administered in combination with CAR T cells. In addition CAR T cells engineered to express the TIM-4 fusion proteins described herein are also provided and may be used in the methods described herein.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 38/17 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
Disclosed herein are effector domains. The effector domains may be used with, for example, Cas proteins and CRISPR-Cas systems. The effectors may be used in combination with a Cas protein to form a fusion protein. The effectors may also be used in combination with an antibody that binds to a peptide epitope, wherein the peptide epitope is fused to a Cas protein. The compositions and methods comprising the effectors may be used to modulate gene expression.
G6PC G6PC transgene into a target gene locus in a subject in need thereof, thereby allowing for stable expression of a therapeutic protein (e.g., glucose-6-phosphatase) and reversal and/or treatment of disease symptoms in the subject.
A novel localized, mechanical HIFU (LM-HIFU) transcatheter device that can ablate cancer cells and disrupt the stromal barrier in tumors, enhancing the efficacy of therapeutics and increasing immune cell infiltration. A miniaturized dual-lumen catheter device is configured to deliver M-HIFU to a tumor that does not have the anatomic limitations of conventional HIFU, and enables access to a primary or metastatic tumor regardless of the location.
A61B 17/22 - Instruments, dispositifs ou procédés chirurgicaux, p.ex. tourniquets pour l'élimination non prévue ailleurs des obstructions dans les vaisseaux sanguins
A61M 5/168 - Moyens pour commander l'écoulement des agents vers le corps ou pour doser les agents à introduire dans le corps, p.ex. compteurs de goutte-à-goutte
36.
COMPOSITIONS AND METHODS FOR IMPROVED MALONYL-COA BIOSYNTHESIS USING 2-STAGE DYNAMIC METABOLIC CONTROL
Methods and microorganisms for improved malonyl-CoA flux and production of products having malonyl-CoA as a precursor. The methods comprise dynamically regulating, in a stationary phase of a method, a nitrogen regulatory protein. The methods may dynamically regulate more than one gene.
Disclosed herein are DMZ-derived compositions for and methods of modulating the expression and/or function of disease associated and/or diseasing causing secondary RNA structures and tertiary RNA structures.
C07C 257/10 - Composés contenant des groupes carboxyle, l'atome d'oxygène, lié par une liaison double, d'un groupe carboxyle étant remplacé par un atome d'azote lié par une liaison double, cet atome d'azote n'étant pas lié de plus à un atome d'oxygène, p.ex. imino avec remplacement de l'autre atome d'oxygène du groupe carboxyle par des atomes d'azote, p.ex. amidines
C07C 243/00 - Composés contenant des chaînes d'atomes d'azote liés entre eux par des liaisons simples, p.ex. hydrazines, triazanes
A61K 31/655 - Composés azoïques(-N=N-), diazoïques (=N2), azoxy (N-O-N ou N(=O)-N), azido (-N3) ou diazoamino (-N=N-N)
38.
COMPOSITIONS FOR AND METHODS OF MODULATING RNA STABILITY
Disclosed herein are compositions for and methods of modulating the expression and/or function of disease associated and/or diseasing causing secondary RNA structures and tertiary RNA structures.
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p.ex. relations structurelles ou fonctionnelles ou alignement de structures
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
39.
QUANTUM COMPUTER BASED ON MANIPULATION OF ION CHAINS
The use of multiple ion chains in a single ion trap for quantum information processing (QIP) systems is described. Each chain can have its own set of laser beams with which to implement and operate quantum gates within that chain, where each chain may therefore correspond to a single quantum computing register or core. Operations can be performed in parallel across all of these chains as they can be treated independently from each other. To implement and operate quantum gates between different chains, neighboring chains are merged into a single, larger chain, in which one can perform quantum gates between any of the ions in the larger chain. The combined chains can then be separated again by another shuttling event as needed. To implement and operate quantum gates between ions which do not occupy neighboring chains, swap gates can be used via a sequence of intervening chains.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
40.
COMPOSITIONS AND METHODS FOR DETECTING, PREDICTING RISK OF DEVELOPING, AND TREATING LEPTOMENINGEAL DISEASE
This disclosure provides compositions and methods for detecting, methods for predicting a risk of developing, and methods for treating systemic and brain parenchymal metastases including leptomeningeal disease (LMD). In particular, provided herein are methods for detecting and/or predicting a risk of developing systemic and brain parenchymal metastases including LMD in a subject (e.g., a human subject) through identifying the presence or absence of integrin a6 and/or breast cancer cells (BCCs) expressing integrin a6 in a sample obtained from the subject. In addition, provided herein are methods for treating, ameliorating, or preventing systemic and brain parenchymal metastases including LMD in a subject through inhibiting expression and/or activity of one or more of integrin a6, BCCs expressing integrin a6, neuroprotective factor glial cell line-derived neurotrophic factor (GDNF), and neural cell adhesion molecule (NCAM).
Disclosed herein is a novel Cas9 protein. Further described herein are fusion proteins, compositions, and methods comprising the same. The novel Cas9 protein may be used, for example, in compositions and methods for modulating expression of a gene, for correcting a mutant gene, and for treating a disease.
Disclosed herein are compositions and methods for modulating T cells. For example, the compositions and methods may be used to increase memory T cells. The compositions and method may be used in combination with Adoptive T Cell Therapy (ACT) to enhance the ACT.
Disclosed herein are methods for the treatment of Pompe Disease comprising administering a recombinant AAV (rAAV) vector comprising a rAVV genome comprising a heterologous nucleic acid encoding an acid alpha-glucosidase (GAA) polypeptide operatively linked to a liver-specific promoter, wherein the subject is withdrawn or not administered enzyme replacement therapy (ERT).
A61K 38/47 - Hydrolases (3) agissant sur des composés glycosyliques (3.2), p.ex. cellulases, lactases
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 3/00 - Médicaments pour le traitement des troubles du métabolisme
Disclosed herein are compositions comprising a chimeric fusion protein targeting phosphatidylserine on the surface of hematological cancer cells and methods of using the compositions to treat a hematological cancer in a subject.
C07K 16/18 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Disclosed herein are compositions comprising a chimeric antigen receptor targeting phosphatidylserine on the surface of cancer cells and methods of using the compositions to treat cancer in a subject.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 14/71 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire pour des régulateurs de croissance
Technologies for performing error correction in a quantum circuit of a quantum computing system are disclosed. A quantum error correction code (QECC) is selected. The QECC is associated with a codespace. The quantum computing system identifies, based on one or more properties of the QECC, one or more diagonal physical gates in the quantum circuit that induces a target logical gate and preserves the codespace. The quantum computing system configures the quantum computing circuit to implement a quantum error correction protocol using the QECC and at least one of the identified diagonal physical gates.
G06N 10/40 - Réalisations ou architectures physiques de processeurs ou de composants quantiques pour la manipulation de qubits, p.ex. couplage ou commande de qubit
B82Y 10/00 - Nanotechnologie pour le traitement, le stockage ou la transmission d’informations, p.ex. calcul quantique ou logique à un électron
G06F 11/00 - Détection d'erreurs; Correction d'erreurs; Contrôle de fonctionnement
H03K 19/195 - Circuits logiques, c. à d. ayant au moins deux entrées agissant sur une sortie; Circuits d'inversion utilisant des éléments spécifiés utilisant des dispositifs supraconducteurs
47.
SYSTEMS AND DEVICES FOR COUPLING METABOLOMICS DATA WITH DIGITAL MONITORS FOR PRECISION HEALTH
THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (Canada)
Inventeur(s)
Kaddurah-Daouk, Rima
Wishart, David
Yahya Rayat, Dorsa
Abrégé
The present disclosure describes, in part, devices, systems, and methods for connecting metabolomic measurements to big data being generated by sensors captured in databases to enable monitoring of metabolic health at molecular level to map disruptions in biochemical processes in each individual that can inform about basis of disease and ways to correct for such defects tailored for each individual.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/083 - Mesure du taux de métabolisme en utilisant un essai respiratoire, p.ex. mesure du taux de consommation d'oxygène
Disclosed herein are compositions for and methods of treating, preventing, and/or mitigating pain, including both acute and chronic pain, post-surgical pain, cancer pain, injury pain, and pain associated with bone fracture. Disclosed herein are compositions for and methods of providing non-opioid analgesia in a subject in need thereof.
A61K 31/7076 - Composés ayant des radicaux saccharide et des hétérocycles ayant l'azote comme hétéro-atome d'un cycle, p.ex. nucléosides, nucléotides contenant des cycles à six chaînons avec l'azote comme hétéro-atome d'un cycle contenant des pyrimidines condensées ou non-condensées contenant des purines, p.ex. adénosine, acide adénylique
A61K 47/10 - Alcools; Phénols; Leurs sels, p.ex. glycérol; Polyéthylène glycols [PEG]; Poloxamères; Alkyléthers de PEG/POE
A61K 47/16 - Composés organiques, p.ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant de l'azote
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
A61P 25/36 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance aux opiacés
Systems and methods for producing an ultrafast functional photoacoustic microscopy system are disclosed herein. Such systems are configured to enable the imaging of microvasculature and functional dynamics of tissue samples with a broad field of view and high spatial resolution. According to several disclosed embodiments, a combination of a Raman path and a polygon scanner in water immersion and air immersion environments enables rapid imaging of target materials.
A DNA synthesis technology that relies on sequence-directed, multiplexed ligations to enable template-independent, exponential synthesis of gene- or genome-length DNA. This approach relies on well characterized and optimized enzymes and thus does not require further protein engineering. This approach is amenable to cost-effective automation and thus will enable cost-effective DNA "printers".
The present disclosure provides devices, systems, and methods relating to performing a medical procedure. In particular, the present disclosure is directed to devices, systems, and methods for accurately positioning and securing a body implant in a subject. A template corresponds to the implant, and the template is configured to mark a desired location in a patient prior to positioning the implant at the desired location.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
Recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to coronavirus spike protein. Herein, monoclonal antibodies were recombinantly derived from isolated B cell from coronavirus infected individuals. Such antibodies bind various epitopes on the coronavirus spike protein and are neutralizing. The invention provides methods for using the inventive antibodies in prophylactic and/or therapeutic methods to prevent or treat coronavirus infection.
The present disclosure describes, in part, biomarkers for the identification of aggressive prostate cancer by determining a castration-resistant prostate cancer (CRPC) evolutionary signature of prostate cells, and methods of use thereof.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
54.
COLLAGEN-BASED MULTILAYER REGENERATIVE VASCULAR GRAFT WITH BIOACTIVE LUMINAL COATING
FUNDACIÓN CARDIOINFANTIL - INSTITUTO DE CARDIOLOGÍA (Colombie)
UNIVERSIDAD DE LOS ANDES (Colombie)
UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (USA)
Inventeur(s)
Briceño Triana, Juan Carlos
Cruz Jimenez, Juan Carlos
García Brand, Andrés Julián
Kim, Seungil
Damore, Antonio
Muñoz Camargo, Carolina
Wagner, William R.
Rodriguez Soto, Maria Alejandra
Sandoval, Nestor
Segura, Tatiana
Suarez Vargas, Natalia Andrea
Abrégé
The present invention relates to a regenerative vascular graft comprising a collagen-based multilayer porous matrix and a functional coating with pro-endothelial peptides and a hydrophilic polymer, and to a production method thereof. The graft of the invention enables vascular conduits integrated into native tissue to be obtained, providing blood flow continuity in a manner similar to the physiological way. This is achieved by regenerating the vascular wall on a substrate that responds in a controlled manner to the inflammatory response and operates optimally under haemodynamically complex conditions while stimulating the formation of a functional endothelium and the repopulation of the matrix.
A61L 27/36 - Matériaux pour prothèses ou pour revêtement de prothèses contenant des constituants de constitution indéterminée ou leurs produits réactionnels
C08L 51/00 - Compositions contenant des polymères greffés dans lesquels le composant greffé est obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone; Compositions contenant des dérivés de tels polymères
55.
COMPOSITIONS AND METHODS FOR IDENTIFYING LIGANDS OF ODORANT RECEPTORS
The present invention relates to compositions and methods for identifying odorant-odorant receptor interactions. In particular, the present invention relates to methods for identifying odorant receptor-odorant interactions based on odorant receptor amino acid sequence and other properties of odorant receptors and odorants. The methods provide, in part, for the broad surveying of OR responses, using an in vivo strategy, against a diverse panel of 10 odorants, followed by using the resulting interaction profiles to uncover relationships between OR responses, odorants, odor molecular properties, and OR sequences.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
56.
BROADBAND APPLICATOR FOR THERMOACOUSTIC SIGNAL GENERATION
An RF applicator has an open-ended waveguide having an aperture and a dielectric cone extending through the aperture and is electrically connected to an RF source that is configured to generate RF energy pulses. A top fin is mounted to an inner top surface of the waveguide and comprises a conductive material, is electrically connected to the RF source, and has dimensions configured to optimize a bandwidth that the RF applicator applies to tissue. A bottom fin is mounted to an inner bottom surface of the waveguide and comprises a conductive material electrically isolated from the RF source, with dimensions configured to optimize a bandwidth that the RF applicator applies to tissue. A dielectric cone is inserted into the waveguide. A filler material between inner surfaces of the waveguide and the solid dielectric cone can fill gaps and has a dielectric constant similar to the dielectric cone.
Disclosed herein are compositions for and methods of treating and/or preventing hereditary aortopathies, treating and/or preventing aortic aneurysms, reducing the need for surgical intervention, slowing and/or inhibiting disease progression, and identifying the risk of aortic aneurysm and/or aortic dissection.
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des acides nucléiques
G16H 50/00 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies
A metallic single-walled carbon nanotube (SWNT) hybrid assembly or superstructure includes a single walled carbon nanotube (SWNT) having a chiral index (n, m) where (n-m)/3 is an integer or 0; and an oligomer or polymer that single-chain wraps the metallic SWNT, wherein the oligomer or polymer is formed of repeat units, wherein each repeat unit has at least one charged functional group per 1-3 nm of oligomer or polymer length. The superstructure is suitable for optical, electro-optical, and spintronic-based device applications.
The present disclosure provides compositions that provide positive allosteric modulator compounds of the beta-adrenergic receptor in combination with a beta-arrestin-biased beta-blocker, such as carvedilol, for the treatment of cardiovascular diseases and disorders, such as hypertension and heart failure, wherein the effectiveness of the beta-blocker is enhanced by positively augmenting carvedilol-stimulated cellular responses.
A61K 31/403 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à cinq chaînons avec un azote comme seul hétéro-atome d'un cycle, p.ex. sulpiride, succinimide, tolmétine, buflomédil condensés avec des carbocycles, p.ex. carbazole
C07C 311/16 - Sulfonamides ayant des atomes de soufre de groupes sulfonamide liés à des atomes de carbone de cycles aromatiques à six chaînons ayant l'atome d'azote d'au moins un des groupes sulfonamide lié à des atomes d'hydrogène ou à un atome de carbone acyclique
60.
COMPOSITIONS AND METHODS FOR THE MODULATION OF PIEZO1 AND TRPV4
Described herein are methods and compositions for treating or reducing the likelihood of a subject developing a pancreatic disease or disorder or keloids. In one embodiment, the method comprises administering a therapeutically effective amount of one or more of a Piezo1 antagonist, a PLA2 antagonist, a TRPV4 antagonist, or combinations thereof.
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
A61P 1/18 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles pancréatiques, p.ex. enzymes pancréatiques
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
The present disclosure provides compounds that block and/or disrupt GABA signaling. The disclosed compounds can decrease and/or inhibit activity, function, expression, and/or accumulation of GAD1, GABABR, and/or GABA and can be used in cancer therapy. The disclosed compounds can be also administered to improve sensitivity to immune check point inhibitor therapy. Assessment of activity, function, expression and/or accumulation of GAD1, GABABR, and/or GABA can be used to determine stage of cancer progression, providing a prognosis and predict responsiveness of a subject to the therapy.
Provided herein are compositions and methods for detection of N6-methyladenosine (m6A) methylation in live cells. The provided compositions include expression systems for detection of m6A methylation and identification of agents that modulate m6A methylation.
A readrRNA (RNA sensing by Endogenous ADAR) molecule is a modular RNA molecule that facilitates cell sensing and detection of a cell type or cell status and/or facilitates delivery of an effector protein to a selected cell. A composition that includes such a modular RNA molecule and another nucleic acid (linked or unlinked to the modular RNA molecule) is a CellREADR (Cell access through RNA sensing by Endogenous ADAR). readrRNA and CellReadR sense the presence of a selected cell RNA and leverages RNA editing mediated by ADAR (adenosine deaminase acting on RNA) for coupling the detection of a cell-defining RNA with translation of one or more effector proteins in a cell or in a mammal.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
Disclosed herein are lipid nanoparticles including a POEGMA-lipid conjugate that can effectively encapsulate and deliver therapeutics without the immune consequences suffered by PEG-based counterparts. An example lipid nanoparticle includes an ionizable lipid, a phospholipid, a sterol, a POEGMA-lipid conjugate, and a therapeutic. Also disclosed herein are pharmaceutical compositions that include the POEGMA-based lipid nanoparticles, methods of treating a disease or disorder, and methods of delivering a therapeutic to a cell.
A readrRNA (RNA sensing by Endogenous ADAR) molecule is a modular RNA molecule that facilitates sensing and detection of a cell type or cell status of a cell, including a cell of a mammalian nervous system, such as a neuronal or non-neuronal cell of the mammalian central and/or peripheral nervous system, and/or facilitates delivery of an effector protein to the selected cell. A composition that includes such a modular RNA molecule and another nucleic acid (linked or unlinked to the modular RNA molecule) is a CellREADR (Cell access through RNA sensing by Endogenous ADAR). CellREADR senses the presence of a selected cell RNA in a cell of a mammalian nervous system via readrRNA and leverages RNA editing mediated by ADAR (adenosine deaminase acting on RNA) for coupling the detection of a cell-defining RNA with translation of one or more effector proteins in a cell of a mammalian nervous system.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
A61K 31/7105 - Acides ribonucléiques naturels, c. à d. contenant uniquement des riboses liés à l'adénine, la guanine, la cytosine ou l'uracile et ayant des liaisons 3'-5' phosphodiester
C07H 21/02 - Composés contenant au moins deux unités mononucléotide comportant chacune des groupes phosphate ou polyphosphate distincts liés aux radicaux saccharide des groupes nucléoside, p.ex. acides nucléiques avec le ribosyle comme radical saccharide
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
C12N 5/10 - Cellules modifiées par l'introduction de matériel génétique étranger, p.ex. cellules transformées par des virus
FLEXIBLE SCOPE DEVICE There is provided a portable medical endoscope comprising: a flexible portion having a proximal end and a distal end, wherein the flexible portion comprises a bending section and a tip at the distal end, and wherein the tip comprises an image-capturing device; a controller portion disposed at the proximal end of the flexible portion, wherein the controller portion comprises: (i) an angulation mechanism coupled to the bending section and the tip, wherein the angulation mechanism controls movement of the tip; and (ii) a handle in a pistol grip configuration; and a detachable monitor configured to releasably engage the controller portion; wherein the flexible portion and the controller portion are integrally formed, waterproof, and capable of withstanding high level disinfection conditions.
A61B 1/00 - Instruments pour procéder à l'examen médical de l'intérieur des cavités ou des conduits du corps par inspection visuelle ou photographique, p.ex. endoscopes; Dispositions pour l'éclairage dans ces instruments
67.
COMPOSITIONS AND METHODS FOR CHARACTERIZING AND TREATING NEURODEGENERATIVE DISORDERS
ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (USA)
DUKE UNIVERSITY (USA)
Inventeur(s)
Chang, Rui
Brinton, Roberta Diaz
Kaddurah-Daouk, Rima
Abrégé
Provided herein are compositions and methods for diagnosing, prognosing, and treating neurodegenerative diseases in a male and female subject at risk of or diagnosed with a neurodegenerative disease. In particular, provided herein are customized metabolite analyses for characterizing and treating neurodegenerative diseases in specific subject groups from a sample from said subject.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
G01N 33/92 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des lipides, p.ex. le cholestérol
68.
COMPOSITIONS AND METHODS FOR TARGETING GPCR FOR THE PREVENTION AND TREATMENT OF PAIN
Methods for treating and preventing pain are described. The methods include administering a therapeutically effective amount of a GPR37L1 ligand to a subject in need thereof. Also described herein are pharmaceutical compositions containing the GPR37L1 ligands.
A61K 31/202 - Acides carboxyliques, p.ex. acide valproïque ayant un groupe carboxyle lié à une chaîne acyclique d'au moins sept atomes de carbone, p.ex. acides stéarique, palmitique ou arachidique ayant au moins trois doubles liaisons, p.ex. acide linolénique
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p.ex. agents antirhumatismaux; Médicaments anti-inflammatoires non stéroïdiens [AINS]
G01N 33/53 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet
69.
COMPOSITIONS AND METHODS RELATING TO EPIGENETIC MODULATION
Disclosed herein are methods of effecting precision epigenetic modulation of one or more genes of interest. Disclosed herein are isolated nucleic acid molecules, viral vectors, rAAV vectors, pharmaceutical formulations, host cells, guide RNAs, and plasmids for use in the disclosed methods.
C07K 14/315 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de bactéries provenant de Streptococcus (G), p.ex. Enterocoques
70.
COMPOSITIONS AND METHODS RELATING TO SARS-COV-2 NEUTRALIZING ANTIBODIES
The ongoing COVID-19 pandemic and the previous SARS outbreak: highlight the danger of recurrent human infections by the emergence of novel pathogenic variants of Coronavirus, which may be resistant to pre-existing human immunity and available vaccines or drugs. Accordingly, described herein is the creation of antibodies that specifically bind S proteins from SARS Co V-2 and related viruses in this family. Described herein are antibody reagents that bind therapeutic targets such as SARS-COV2 spike protein, as well as methods of using such antibody reagents.
The invention is directed to modified HIV-1 envelopes, compositions comprising these modified envelopes, nucleic acids encoding these modified envelopes, compositions comprising these nucleic acids, and methods of using these modified HIV-1 envelopes and/or these nucleic acids to induce immune responses.
Disclosed herein are electrically conductive polymer compositions comprising a polymer and a dispersant, and methods of synthesizing the polymers therein. Also disclosed herein are microelectrode arrays comprising the electrically conductive material and a conductive polymer composition attached to a surface of the electrically conductive material. Further disclosed herein are methods of detecting electrical activity in a cell comprising contacting the microelectrode array with a cell and detecting electrical activity in the cell by covalently attaching the polymer of the conductive polymer composition to a protein on the surface of the cell.
H01B 1/12 - Conducteurs ou corps conducteurs caractérisés par les matériaux conducteurs utilisés; Emploi de matériaux spécifiés comme conducteurs composés principalement d'autres substances non métalliques substances organiques
Disclosed herein are compositions and methods for treating cancer. The methods may include administering to a subject at least one estrogen receptor (ER) modulating drug. The methods may further include administering to the subject at least one additional therapy. Further provided herein are methods of predicting response of a subject to immune checkpoint blockade (ICB) therapy.
A61K 38/00 - Préparations médicinales contenant des peptides
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
75.
MULTI-PORT, HIGH-FLOW PNEUMOPERITONEUM AND SMOKE EVACUATION DISTRIBUTION DEVICES, SYSTEMS, AND METHODS
An insufflation system for creating a high-flow, constant pressure pneumoperitoneum, the system including: a gas flow distribution device including: a housing defining an insufflation chamber; an inlet port on the housing and configured to be connected to an insufflator to provide insufflation gas from the insufflator to the insufflation chamber; and a plurality of outlet ports on the housing configured to be connected to a plurality of trocars, each outlet port configured to be connected to a dedicated one of the plurality of trocars, to concurrently distribute the insufflation gas from the insufflation chamber to each of the plurality of trocars.
he present invention provides methods for using an anionic manganese oxide (MnO) nanoparticle-based nucleic acid scavenger to (1) inhibit viral infection of cells, (2) reduce or inhibit a viral infection of a subject, and (3) reduce viral infection induced inflammation in a subject.
B82B 3/00 - Fabrication ou traitement des nanostructures par manipulation d’atomes ou de molécules, ou d’ensembles limités d’atomes ou de molécules un à un comme des unités individuelles
B82Y 5/00 - Nanobiotechnologie ou nanomédecine, p.ex. génie protéique ou administration de médicaments
77.
COMPOSITIONS FOR THE TREATMENT OF FOOD AND CHEMICAL ADDICTION AND METHODS OF MAKING AND USING SAME
Embodiments of the instant disclosure relate to novel compounds, compositions, and methods for treating health conditions. In certain embodiments, methods of treating health conditions can include administering an effective amount of at least one of the compounds or compositions disclosed herein to a subject having or suspected of having an imbalance in brain dopamine homeostasis.
A61K 31/352 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p.ex. fungichromine ayant des cycles à six chaînons avec un oxygène comme seul hétéro-atome d'un cycle condensés avec des carbocycles, p.ex. cannabinols, méthanthéline
C07D 311/24 - Benzo [b] pyrannes non hydrogénés dans le carbocycle avec des atomes d'oxygène ou de soufre liés directement en position 4 avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement en position 2
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
A61P 25/30 - Médicaments pour le traitement des troubles du système nerveux des états d'abus ou de dépendance
78.
COMPOSITIONS FOR AND METHODS OF TREATING AND/OR PREVENTING GLUTARIC ACIDURIA TYPE-I
Glutaric aciduria type I (GA-1), is a rare neurometabolic organic aciduria caused by glutaryl-CoA dehydrogenase (GCDH) deficiency. It is an autosomal recessive inborn error of lysine and tryptophan catabolism. Disclosed herein are compositions for use in methods of treating and/or preventing Glutaric Aciduria Type 1 and in methods of reprogramming a metabolic pathway.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61P 1/16 - Médicaments pour le traitement des troubles du tractus alimentaire ou de l'appareil digestif des troubles de la vésicule biliaire ou du foie, p.ex. protecteurs hépatiques, cholagogues, cholélitholytiques
79.
SYSTEMS AND METHODS FOR STEREO-EEG IMPLANTATION AND RESECTION SURGERIES
The present disclosure describes innovations to improve the use of stereo-EEG (sEEG) in treating epilepsy. The systems and methods include a fully automated platform for generating patient specific head models, a visualization of the tissue that can be recorded by a set of sEEG electrodes, an automated implantation trajectory planning algorithm that incorporates the tissue that can be recorded by a set of sEEG electrodes, and a dynamic source reconstruction algorithm that can visualize the epileptiform activity.
A61B 5/291 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG]
A61B 5/369 - Modalités, c. à d. méthodes diagnostiques spécifiques Électroencéphalographie [EEG]
A61B 34/10 - Planification, simulation ou modélisation assistées par ordinateur d’opérations chirurgicales
80.
NANOFIBERS TO PRIME ANTIBODY RESPONSES AND METHODS OF USING SAME
Embodiments are directed to nanofiber compositions comprising antigens, such as the fusion peptide (FP) of HIV-1 trimers. The compositions may be used as vaccines themselves, or they may be used in combination with vaccines to enhance the immune response and increase antibody titers.
LUDWIG-MAXIMILIANS UNIVERSITÄT MÜNCHEN (Allemagne)
DEUTSCHES ZENTRUM FÜR NEURODEGENERATIVE ERKRANKUNGEN E.V. (Allemagne)
Inventeur(s)
Saban, Daniel
Yu, Chen
Haass, Christian
Schlepckow, Kai
Abrégé
The present disclosure describes, in part, methods for treating a degenerative and vascular disease of the retina and/or posterior segment of the eye in a subject, the method comprising administering to a subject an effective amount of an antibody or fragment thereof that binds to the same epitope as an antibody comprising a heavy chain variable region and a light chain variable region, wherein: (a) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 4 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 5 wherein the antibody inhibits TREM2 cleavage; or (b) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 6 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO:7, and wherein the antibody inhibits TREM2 cleavage; or (c) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 8 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO:9 or to SEQ ID NO:87, and wherein the antibody inhibits TREM2 cleavage; or (d) the heavy the heavy chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 10 and the light chain variable region comprises a sequence having at least 85% sequence identity to SEQ ID NO: 11 or to SEQ ID NO: 12 or to SEQ ID NO: 13 or to SEQ ID NO: 14, and wherein the antibody inhibits TREM2 cleavage, and methods of screening for a molecule which specifically binds to and inhibits cleavage of human TREM2 between Hisl57 and/or Serl58 on the surface of retinal microglial cells by ADAMIO and/or ADAM17.
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des micro-organismes viables
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
82.
REAGENTS FOR SITE-SPECIFIC LABELING OF PROTEINS WITH RADIOHALOGENS, AND METHODS OF MAKING AND USING THE SAME
THE RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK (USA)
Inventeur(s)
Zalutsky, Michael
Feng, Yutian
Vaidyanathan, Ganesan
Zeglis, Brian
Sarrett, Samantha
Abrégé
The present disclosure provides, in part, methods for site-specific labeling of proteins/peptides with radiohalogens and compositions resulting from said methods.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
C07D 271/113 - Oxadiazoles-1, 3, 4; Oxadiazoles-1, 3, 4 hydrogénés avec des atomes d'oxygène, de soufre ou d'azote, liés directement aux atomes de carbone du cycle, les atomes d'azote ne faisant pas partie d'un radical nitro
Methods, systems and computer program products for determining a property for a sample having a target region using ultrasound data from an ultrasound scanner include generating at least one spatial coherence curve based on ultrasound backscatter data in the target region, the spatial coherence curve comprising coherence values as a function of depth in the sample; and determining a property for a sample in response to the spatial coherence curve as a function of depth.
Disclosed are high density POEGMA-biologically active agent conjugates that have advantageous pharmacokinetics, while also having a reduced or eliminated host-immune response. An example conjugate includes a biologically active agent and a plurality of POEGMA molecules conjugated to the biologically active agent, each POEGMA molecule having a poly(methyl methacry late) backbone and a plurality of side chains covalently attached to the backbone, each side chain including 2 to 9 monomers of ethylene glycol repeated in tandem. Also disclosed are methods of reducing the immunogenicity of a polymer-biologically active agent conjugate.
A61K 47/58 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. poly[méth]acrylate, polyacrylamide, polystyrène, polyvinylpyrrolidone, alcool polyvinylique ou résine d’acide sulfonique de polystyrène
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
85.
SYSTEMS AND METHODS FOR APPLANATION TONOMETRY AND TONOGRAPHY
Systems, devices, and methods for measuring intraocular pressure of the eye are disclosed. More particularly, the improved systems, devices, and methods enable the use of applanation tonometry and tonography to make such measurements using a portable, handheld applanation device. The applanation devices apply a constant fixed force to the surface of the eye. The resulting applanation mire can be captured by an image-capturing device and the intraocular pressure can be calculated using a provided algorithm based on the applanation mire and a known reference with respect to the eye.
A61B 3/16 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux du type à mesure objective, c. à d. instruments pour l'examen des yeux indépendamment des perceptions ou des réactions du patient pour mesurer la pression intraoculaire, p.ex. tonomètres
A61B 3/00 - Appareils pour l'examen optique des yeux; Appareils pour l'examen clinique des yeux
86.
COMPOSITIONS FOR AND METHODS OF LONG-TERM INTEGRATION OF CIRCUITS USING CONNEXINS
Gap junctions (electrical synapses) enable direct flow of ions and small molecules between two cells and play a prominent role in broadly synchronizing electrical activity in many organs such as the heart and the brain. Many Cxs can form single-isoform hemichannels. Gap junctions are membrane spanning channels that connect the cytoplasm of apposed cells, allowing for the passage of small molecules and ions. Disclosed herein are compositions for use in methods of precision editing circuits using designer connexins.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A61K 31/7088 - Composés ayant au moins trois nucléosides ou nucléotides
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
87.
LAYERED DOUBLE HYDROXIDE PARTICLES IN HYDROGEL MATRICES
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD (Royaume‑Uni)
Inventeur(s)
Li, Dapeng
Mcmichael, Andrew, James
Brackenridge, Simon
Gillespie, Geraldine
Azoitei, Mihai
Walters, Lucy, C.
Saunders, Kevin, O.
Haynes, Barton, F.
Abrégé
The present invention provides affinity matured recombinant monoclonal antibodies (mAbs) and fragments that bind specifically to an HLA-E- peptide complex, including HLA-E-VL9 complexes, and. regulate the cytotoxicity effector cell function of NK and/or CD8+ T-cells positive for cell-surface expression of NKG2A ("NKG2A+"). Herein, monoclonal antibodies were recombinant.lv derived from isolated functional HLA-E- VL9-specific mAbs from HLA-E- VL9 peptide- immunized HLA-B transgenic mice and from the naive human B cell repertoire. Such antibodies are capable of regulating effector cell cytotoxicity' and can preferentially recognize HLA-E- VL9 peptide complexes expressed on the surface of tumor cells. The monoclonal antibodies were subject to one or more rounds of affinity7 maturation. The invention provides methods for using affinity matured HLA-E- VL9 mAbs to modulate NK and/or CD8+T- cell function as part of immunotherapeutic strategies.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
G01N 33/569 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour micro-organismes, p.ex. protozoaires, bactéries, virus
89.
NEXT GENERATION VACCINES COMPRISING ANTIGENIC LIBRARIES AND METHODS OF MAKING AND USING SAME
The present invention provides protein libraries comprising variants of an antigenic viral protein that each have a different set of mutations at one or more hypervariable sites. Nucleic acid and vector libraries encoding the protein libraries, vaccines comprising the libraries, and methods of inducing an immune response against the antigenic viral protein are also provided.
Techniques and systems for automated social synchrony measurements which can identify behaviorally relevant social synchrony are provided. A method for automated social synchrony measurements can include receiving a recording of a social interaction between a first participant and a second participant; for each feature, extracting, from the recording, a feature time series pair comprising a first time series of the first participant and a second time series of the second participant; for each feature time series pair, determining an individual social synchrony level between the feature time series pair using characteristics of the derivative dynamic time warping path of the feature time series pair; analyzing the determined individual social synchrony level of every feature time series pair to identify a set of the features related to the prediction target; and generating a notification for at least one feature based on the determined individual social synchrony level.
G06V 10/80 - Fusion, c. à d. combinaison des données de diverses sources au niveau du capteur, du prétraitement, de l’extraction des caractéristiques ou de la classification
G06V 40/16 - Visages humains, p.ex. parties du visage, croquis ou expressions
G06V 40/18 - Caractéristiques de l’œil, p.ex. de l’iris
G06V 40/20 - Mouvements ou comportement, p.ex. reconnaissance des gestes
G10L 25/63 - Techniques d'analyses de la parole ou de la voix qui ne se limitent pas à un seul des groupes spécialement adaptées pour un usage particulier pour comparaison ou différentiation pour estimer un état émotionnel
91.
RAPID EXPRESSION AND PURIFICATION OF THERMOSTABLE PROTEINS INCLUDING TAQ POLYMERASE
Genetically modified microorganisms enabling the simple, rapid production and purification of thermostable polymerases are described. Methods of rapid purification of a thermostable polymerase are described including the steps of autoinducible expression achieving high titers of soluble protein; autolysis of cells post harvest, autohydrolysis of host nucleotides through expression of a thermolabile endonuclease; and heat denaturation and precipitation of contaminating proteins. Polymerases are obtained with > 95% purity, and are readily usable in standard PCR.
An apparatus for perfusing an organ includes: an organ chamber configured to provide physical protection to an organ; at least one fluid flow loop from an outlet connection of the organ chamber, through an oxygenator, through a pump, and to an inlet connection of the organ chamber; and a container enclosing the components of the apparatus, wherein the apparatus is portable.
Disclosed herein are adeno-associated virus (AAV) vectors comprising capsid protein variants. Also disclosed herein are pharmaceutical compositions comprising these AAV vectors and capsid protein variants as well as methods of making such vectors and capsid protein variants. Disclosed herein are methods of using the disclosed AAV vectors and disclosed capsid protein variants.
C07K 14/005 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant de virus
C40B 40/02 - Bibliothèques contenues ou présentées dans des micro-organismes, p.ex. des bactéries ou des cellules animales; Bibliothèques contenues ou présentées dans des vecteurs, p.ex. des plasmides; Bibliothèques contenant uniquement des micro-organismes ou des vecteurs
C40B 40/08 - Bibliothèques comprenant de l'ARN ou de l'ADN codant des protéines, p.ex. bibliothèques de gènes
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
94.
COMPOSITIONS FOR AND METHODS OF IMPROVING VIRAL VECTORS
Disclosed herein are viral vectors for use in methods of developing HDAC-depleted cells. Disclosed herein are methods of increasing packaging capacity, increasing the titer, increasing the expression capacity, and decreasing the immunogenicity and/or toxicity of an optimized viral vector generated in HDAC-depleted cells.
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p.ex. oligonucléotides anti-sens
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteurs; Vecteurs; Utilisation d'hôtes pour ceux-ci; Régulation de l'expression
95.
VOLUME REDUCTION NON-SEWERED SINGLE UNIT TOILET SYSTEM
COLORADO STATE UNIVERSITY RESEARCH FOUNDATION (USA)
CRANFIELD UNIVERSITY (Royaume‑Uni)
Inventeur(s)
Yee, Shannon
Azevedo, Kyle
Gaylo, Ryan
Sherman, Kristine
Turner, Travis
Dimenichi, Dante, Iii
Holcombe, Wiley D.
Holmes, Jonathan
Noel, Alexis
Williams, Aimee N.
Richter, Stephanie
Hawkins, Brian
Miller, Graham
Trotochaud, Lena
Gruendl, Harald
León, Oscar Estrada
Sampl, Georg
Lehmann, Roland
Hasler, David
Seiler, Christian
Farrér, Christoph
Forrer, Christian
Staub, Andreas
Glatthard, Janine
Schlauri, Mathias
Caduff, Marco
Fischer, Florian
Frasson, Valdinei
Gemperli, Adrian
Rüdisüli, Daniel
Davey, Chris
Mcadam, Ewan
Ravndal, Kristin
Mizia, John
Willman, Matt
Abrégé
Non-sewered toilet system and method for separation and treatment of human waste are described. The system can include a frontend system with a solids separator (100), a buffer tank separation system (200), a liquid waste treatment system (300), and a solids waste treatment system (500). The solids separator can separate combined human waste including feces or urine into a separated solids portion and a separated liquid portion. The buffer tank separation system can deliver a solids portion of the input stream to the solids collection tank and deliver the liquids portion to the liquids collection tank. The liquid waste treatment system can receive liquid waste collected in the liquids collection tank and deliver a usable water. The solids waste treatment system can receive a slurry from the solids collection tank, heat the slurry to inactivate pathogens, and form feces cakes with a filter press. A combustor can reduce the feces cakes to ash.
C02F 9/00 - Traitement en plusieurs étapes de l'eau, des eaux résiduaires ou des eaux d'égout
C02F 1/44 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dialyse, osmose ou osmose inverse
C02F 1/74 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par oxydation au moyen de l'air
C02F 11/121 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par déshydratation mécanique
C02F 11/123 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par déshydratation mécanique à l’aide de filtres à bandes
C02F 11/128 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par déshydratation mécanique utilisant des procédés discontinus
C02F 11/16 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement à l’aide de lits séchants ou compostants
C02F 11/18 - Traitement des boues d'égout; Dispositifs à cet effet par conditionnement thermique
C02F 11/06 - Traitement des boues d'égout; Dispositifs à cet effet par oxydation
C02F 11/122 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par déshydratation mécanique à l’aide de filtres-presses
E03D 1/14 - Réservoirs déversant des quantités d'eau variables
E03D 5/014 - Installations particulières d'appareils de chasse combinés avec des éléments obturateurs mobiles dans l'orifice d'évacuation de la cuvette avec dispositifs pour retirer séparément liquides et solides
E03D 11/11 - Cuvettes combinées avec un réservoir, p.ex. contenant un appareil pour la désinfection ou la désintégration
B01D 33/04 - Filtres avec éléments filtrants mobiles au cours de l'opération de filtration à bandes filtrantes ou analogues supportées par des cylindres imperméables pour la filtration
B01D 29/35 - Eléments filtrants autoportants agencés pour la filtration à courant dirigé vers l'extérieur
B01D 29/90 - Filtres à éléments filtrants stationnaires pendant la filtration, p.ex. filtres à aspiration ou à pression, non couverts par les groupes ; Leurs éléments filtrants comportant des dispositifs d'alimentation ou d'évacuation d'alimentation
E03F 1/00 - Procédés, systèmes ou installations pour l'évacuation des eaux d'égout ou des eaux d'orage
C02F 1/20 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par dégazage, c. à d. par libération des gaz dissous
System and method for volume reduction solids treatment for fecal waste are described. The system can include a pasteurizer (102) configured to receive a slurry batch and heat the slurry batch at an elevated temperature for a time period to produce a pathogen free slurry. The system can also include a mechanical dewatering press (104) configured to compress the pathogen free slurry to separate a liquid phase from a volume reduced solid waste. The volume reduced solid waste being formed into a feces cake. The system can also include a means to remove the liquid phase and a drying tunnel (106) comprising a conveyor housed and an air duct system. The air duct system configured to propel forced air over the feces cake.
C02F 11/122 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par déshydratation mécanique à l’aide de filtres-presses
C02F 11/18 - Traitement des boues d'égout; Dispositifs à cet effet par conditionnement thermique
C02F 11/16 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement à l’aide de lits séchants ou compostants
C02F 11/13 - Traitement des boues d'égout; Dispositifs à cet effet par déshydratation, séchage ou épaississement par chauffage
97.
RADIOLABELED PARP INHIBITOR CONJUGATES FOR CANCER TREATMENT
C07D 403/02 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles
C07D 403/10 - Composés hétérocycliques contenant plusieurs hétérocycles, comportant des atomes d'azote comme uniques hétéro-atomes du cycle, non prévus par le groupe contenant deux hétérocycles liés par une chaîne carbonée contenant des cycles aromatiques
A61K 51/00 - Préparations contenant des substances radioactives utilisées pour la thérapie ou pour l'examen in vivo
98.
COMPOSITIONS FOR AND METHODS OF PROMOTING RESPIRATORY HEALTH
ANN AND ROBERT H. LURIE CHILDREN'S HOSPITAL OF CHICAGO (USA)
Inventeur(s)
Kelly, Matthew
Seed, Patrick
Abrégé
Disclosed herein are biotherapeutics comprising probiotics or a consortium of probiotics. Disclosed herein are biotherapeutics comprising factors secreted from probiotics or factors secreted from a consortium of probiotics. Disclosed herein are also pharmaceutical formulations comprising a disclosed biotherapeutic. Also disclosed are methods of promoting respiratory health, reducing the risk of developing and infection, treating and/or preventing a bacterial colonization and/or infection, and modulating microbial diversity and/or composition.
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
99.
D2C7 EGFR AND EGFR VIII BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR CONSTRUCTS AND METHODS OF MAKING AND USING SAME
The present disclosure provides, in part, a novel chimeric antigen receptor (CAR) T cell that will simultaneously target wildtype EGFR (EGFRwt) and the viii variant (EGFRvlll), comprising a extracellular antigen binding region, a transmembrane domain, and intracellular domain comprising at least one co-stimulatory domain, and methods of making and using same.
A method of rapid coherent synthetic wavelength interferometric absolute distance measurement includes receiving, from an optical system, an image from an object scene of at least two distinct wavelengths of light, each wavelength's light source having a coherence length greater than a desired ambiguity length of the absolute distance measurement, and whose synthetic wavelength in combination provides the desired ambiguity length of the absolute distance measurement. A phase-based approach, a magnitude-based approach, or an envelope of the magnitude-based approach can be taken to determine an interference between light returning from the object scene and light traversing a separate reference arm path of the optical system and calculate an optical distance to an object in the object scene.
brevets
